PFE (previous P2 data: 66/37/20 for ACR 20/50/70 respectively - the P3 numbers are actually worse)
So will /LLYINCY's number in phase 3, as they still modify dose regimen.
INCY & LLY have a better mousetrap
It's a mistake to say one is better than the other by comparing topline efficacy data in RA, MS. 5 or 10% better numeric efficacy won't make any difference unless safety profile for long term use is better as well.
Market Data 
Markets 
AI
